cediranib + docetaxel

Cediranib + docetaxel is an investigational combination therapy evaluated primarily for the treatment of advanced solid tumors, including metastatic castration-resistant prostate cancer. Cediranib is an oral, potent inhibitor of all three vascular endothelial growth factor receptors (VEGFR-1, -2, and -3), thereby inhibiting tumor angiogenesis. Docetaxel is a well-established chemotherapeutic agent (a taxane) that disrupts microtubule function, resulting in cell cycle arrest and apoptosis. The combination aims to exploit both antiangiogenic (cediranib) and cytotoxic (docetaxel) mechanisms for enhanced antitumor efficacy. Clinical data to date suggest limited additional benefit over docetaxel alone with an increased risk of toxicity, especially in the treatment of metastatic castration-resistant prostate cancer.

Other names

cediranib maleate + docetaxel